Research Results for New Triple-Negative Breast Cancer Combination Treatment

What if a new drug combo could finally help patients with the toughest breast cancer? Triple-negative breast cancer, or TNBC, is one of the most aggressive forms of breast cancer. It’s called “triple negative” because the cancer cells lack three common receptors — estrogen, progesterone, and HER2 — that some other breast cancers have. That matters because most targeted therapies work by attaching to one of those receptors. Without them, TNBC doesn’t respond to hormone therapy or HER2-targeted drugs, so doctors often rely on chemotherapy first. TNBC accounts for about 15–20% of breast cancer cases and is especially hard to treat once it spreads.